Physician profile
Ali Atoot
NPI 1700345543
$4,487.52
in general payments reported to CMS, 2019-2025
22 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,985 · 2024: $1,284 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764 · Travel and Lodging: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,764.19 |
| Travel and Lodging | $723.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,700.17 | 2023-2025 | Proclaim, Eterna |
| Pacira Pharmaceuticals Incorporated | $765.29 | 2023 | Iovera |
| Nevro Corp. | $337.90 | 2023 | Senza |
| Saluda Medical Americas, INC. | $278.42 | 2024 | Evoke |
| Biotronik Nro, INC. | $209.10 | 2024-2025 | Prospera |
| Nalu Medical, INC. | $177.76 | 2025 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $162.03 | 2023 | |
| Madrigal Pharmaceuticals | $149.99 | 2025 | Rezdiffra |
| Smith+Nephew, INC. | $142.61 | 2024 | Real Intelligence, Intellio Link Werewolf |
| Medtronic, INC. | $79.83 | 2023-2025 | Invos, Intellis Adaptivestim |
| Novo Nordisk INC | $78.92 | 2024-2025 | Ozempic, Rybelsus |
| Spr Therapeutics, INC | $66.00 | 2023 | Sprint Pns System |
| Lilly USA, LLC | $61.91 | 2025 | Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $53.99 | 2025 | Zoryve |
| Exact Sciences Corporation | $53.11 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $39.05 | 2025 | |
| Mindray Ds USA, INC. | $37.08 | 2024 | Te7 Max, Te X |
| Fisher & Paykel Healthcare INC | $24.38 | 2025 | Fisher & Paykel Healthcare |
| Conmed Corporation | $22.04 | 2024 | Airseal |
| Foundation Fusion Solutions, LLC | $18.33 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $14.87 | 2025 | |
| Abbvie INC. | $14.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Atoot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.